{ "schemaVersion": "deck-intelligence.v1", "id": "019de076-08a6-76d8-a7d9-b68643d71f6f", "slug": "3a0354fd1e64f16191ffa0e33db132fd", "title": "MaxCyte | Investor Presentation Deck | 19 slides", "subtitle": "MaxCyte · 2023-10", "author": "MaxCyte", "date": "2023-10-01 00:00:00", "pageCount": 19, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de076-08a6-76d8-a7d9-b68643d71f6f", "slug": "3a0354fd1e64f16191ffa0e33db132fd", "title": "MaxCyte | Investor Presentation Deck | 19 slides", "rawTitle": "MaxCyte | Investor Presentation Deck | 19 slides", "authorId": "maxcyte", "authorName": "MaxCyte", "authorDisplay": "MaxCyte", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-10__maxcyte__investor-pres__3a0354fd.pdf", "sourceUrl": "https://www.slidebook.io/company/maxcyte/presentation/3a0354fd1e64f16191ffa0e33db132fd/", "sourceDate": "2023-10-15 00:00:00", "presentationDate": "2023-10-01 00:00:00", "ingestedAt": "2026-04-30 22:15:25.196058+00", "status": "ready", "pageCount": 19, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "medical-devices", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-10__maxcyte__investor-pres__3a0354fd", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 19, "pagesIndexed": 19, "pagesWithImages": 19, "pagesWithMetadata": 19, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 104, "chartCount": 7, "metricSlides": 0, "toolMatches": 8, "documentToolMatches": 0, "frameworkMatches": 7, "arcMatches": 1, "beatMatches": 5, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "evidence": "The deck follows a structure similar to the Sequoia Pitch, with sections on problem, solution, market size, product, business model, and team.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:38:41.246887+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 8, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Problem", "beatId": "993aae5c-8a2b-466e-8ac3-325090cd909e", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 7-8 discuss market sizing and industry challenges.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 8, "name": "Solution", "beatId": "c85bce06-a0b6-4a3f-abe1-f93499e324ad", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 8-9 present the ExPERT platform as a solution to industry challenges.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Market Size", "beatId": "20322ef1-1a83-4f62-84a0-1210f95cd1b6", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Slide 7 discusses market sizing.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 10, "name": "Business Model", "beatId": "976459c1-7ff0-4493-b615-fc2c763afd88", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "Slides 10-11 present MaxCyte's business model.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 5, "name": "Traction", "beatId": "dfb91984-6b87-4a1e-a5ea-23a6ffe055b6", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": null, "evidence": "Slides 5-6 showcase MaxCyte's traction and value creation.", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "01f711fa-869f-4bfb-90f0-c7ddf9b8181f", "evidence": "The deck implies that not investing in cell-based therapies would mean missing out on significant market opportunity.", "position": 0, "objective": "What if we don't invest in cell-based therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:41.4904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 19, "from": 18, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "e0b404df-b36e-43ac-bec8-608ea5c66a7d", "evidence": "Slides 18-19 discuss 2023 YTD summary and outlook, implying that now is a good time to invest.", "position": 1, "objective": "Why now is the time to invest in MaxCyte", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:41.532647+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "b582370c-14f6-4e98-92f0-b8d11f01b3bb", "evidence": "The slide includes a title, logo, and disclaimer, which are typical elements of a cover slide.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:12.397186+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1a3019d7-2fb3-472b-b796-28256dcf85b1", "evidence": "The slide provides a brief overview of the company's technology and business model.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:12.528579+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "778bc7f7-82ab-4f9e-b13f-7f4493657027", "evidence": "The ExPERT™ Platform Enabling Non-Viral Cell Engineering, targeted at customers in the cell therapy and drug discovery markets.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:30.286058+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Value Proposition Canvas", "slug": "value-proposition-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-85a9-713f-8a1c-b6e5af5cc6cd", "version": 1, "bodyDocId": null, "description": "Mapping customer jobs/pains/gains to your value proposition", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "dbb3d6b9-666f-4844-8a79-f0ec2fc91d06", "evidence": "Enabling customers to use... Agnostic to cell type... High Performance: >90% transfection efficiencies, >90% cell viabilities", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:34:30.33202+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "67b4280f-eb14-4416-ab17-f14bbc581877", "evidence": "Stacked area chart showing revenue growth over time", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:34:30.506148+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "bcb47f47-ac2f-41fb-b413-80a39daa7a62", "evidence": "The slide contains lists of bullet points highlighting various diseases and technologies.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:39:21.409417+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "815b7d7a-ba73-4c1a-ad13-f2017e833ce2", "evidence": "2023 YTD Summary and Outlook for 2023+, list/bullet: Revenue guidance $34-36M; Launch new PAs; VLx launch; Global commercial support; Core technology expansion.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:30.723208+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Storytelling: the closing ask", "slug": "closing-ask", "status": "active", "bestFor": null, "canonId": "019df269-24e0-70ab-8dd9-983832c1c665", "version": 1, "bodyDocId": "019df269-24bc-7554-b88d-245127606b8d", "description": "The single most important slide in the deck — after the cover. The final", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "c54bc30f-cba8-4154-a23a-0a3440e66f3a", "evidence": "Thank you! Any questions?, title/headline: Thank you! Any questions?", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:30.810179+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "0f75232c-4e64-4c44-bc50-ae26fbecf01f", "evidence": "Chronological progression of company milestones", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:54.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "timeline" }, { "matchId": "55164560-7bea-4e95-82d4-d18318ef3530", "evidence": "Maps specific industry pain points to corresponding product solutions.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:55.74+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "before-after-bridge" }, { "matchId": "b42f0d81-ac18-4c0f-aff2-d8d21b96c41d", "evidence": "Explicitly stated as 'Razor/Razor Blade Economics' in the revenue model flow.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:56.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "razor-razor-blade" }, { "matchId": "73a0c7f9-60ae-428d-9400-24a4ef15afee", "evidence": "Explicit mention of 'Razor/Razor Blade Economics' and structure of recurring revenue from disposables.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:27:05.347+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "razor-blade-model" }, { "matchId": "188b8601-38ed-4782-a11b-21cf4fa502ec", "evidence": "The chart maps revenue stages against a chronological progression of clinical development.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:57.007+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "timeline" }, { "matchId": "29772201-3ded-4195-b4a3-a9c7d3c34661", "evidence": "Sequential waves representing future growth phases", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:58.039+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "timeline" }, { "matchId": "3401ed1b-7432-4fe4-9e40-6dd3eaac01b6", "evidence": "The slide uses a 6-step linear process flow to represent the business workflow.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:26:58.341+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "process" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/AIMyXWnL3guf4l84M8ToqzH3ayrQ_KGKxiwbUVXFnyQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTAzNTRmZDFlNjRmMTYxOTFmZmEwZTMzZGIxMzJmZC9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 4, "textChars": 249, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:55.605+00", "seconds": 3.019, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/1", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-1", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.4, "x": 0.07, "y": 0.9 }, "kind": "disclaimer", "text": "MaxCyte, expert, ATx, STx, GTx are registered trademarks of MaxCyte, Inc. in the U.S.A. VLx is a trademark of MaxCyte, Inc.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "779fb98c-afd4-4fbb-b657-6945be918f46", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.07, "y": 0.725 }, "kind": "image", "text": "MaxCyte", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91c941ea-346f-40be-8cc7-2e473c913937", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.07, "y": 0.4 }, "kind": "paragraph", "text": "MaxCyte Corporate Presentation\nNASDAQ: MXCT • LSE: MXCT\nOctober 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b70ca00-4ed0-49e4-87ec-861167a0ffda", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.6, "x": 0.07, "y": 0.17 }, "kind": "title", "text": "Driving the Next Generation of Cell-Based Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e2a5834e-2d4c-4524-8b62-e6746ce07bc6", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "b582370c-14f6-4e98-92f0-b8d11f01b3bb", "evidence": "The slide includes a title, logo, and disclaimer, which are typical elements of a cover slide.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:12.397186+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/G37TT2dQZTJ3Ayp6-2uxS8y7lrVHTRhmLMuFwx9KT2Y/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTAzNTRmZDFlNjRmMTYxOTFmZmEwZTMzZGIxMzJmZC9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/LSuC0nQGXdRWlTT1YufHf14nV8oZG3HXb0vAlpQH6PY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTAzNTRmZDFlNjRmMTYxOTFmZmEwZTMzZGIxMzJmZC9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/FNexyBvMMXPQeJSNngkD3XOrcY2XmllFXtWoycaQXOY/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTAzNTRmZDFlNjRmMTYxOTFmZmEwZTMzZGIxMzJmZC9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 19, "componentCount": 3, "textChars": 195, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:57.279+00", "seconds": 4.626, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/2", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-2", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.93, "x": 0.035, "y": 0.245 }, "kind": "disclaimer", "text": "The content of this document (the \"Presentation\") has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (\"FSMA\"), as amended...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.279+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8fb488e3-40d7-44d3-9d42-f0cc8895bbde", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.158, "x": 0.808, "y": 0.058 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.279+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9e87e143-d180-49ce-a444-22829f4aa7f3", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.165, "x": 0.035, "y": 0.075 }, "kind": "title", "text": "Disclaimer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.279+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f4a7da0-11eb-4de3-a709-6ac5dedb0974", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "The slide uses a three-column layout to summarize key value propositions.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 5, "textChars": 759, "nDataPoints": 8, "notes": "The slide uses a three-column layout to summarize key value propositions.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:55.182+00", "seconds": 2.523, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/3", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-3", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.3, "x": 0.04, "y": 0.0016 }, "kind": "list", "text": "With 600+ platforms in place, our proprietary technology unlocks the significant potential of advanced therapeutics. Enables delivery of almost any molecule into almost any cell type. Leads the industry in performance. Extensive product portfolio. ~25% 5-Year CAGR; ~89% gross margins.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "272966ac-a001-4a4e-a305-a21a20845eca", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.36, "y": 0.0016 }, "kind": "list", "text": "Leading the growing next-generation cell therapy market. 20+ years of expertise. 30+ field sales/scientists. Significant collaborations. FDA Master File. Used in 45+ clinical trials.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ca5008f-dc6d-4114-af27-28f2f3ec4313", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.68, "y": 0.0016 }, "kind": "list", "text": "Innovative business model focused on value creation and shared partnership success. 23 SPL partnerships. $2B in potential pre-commercial milestone payments. Focused on diverse portfolio of patient treatments.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e838de30-66d9-4b2a-91f9-2ce9a922698a", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.69, "y": 0.88 }, "kind": "source-note", "text": "*As of December 31, 2022", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "493e6ef8-af87-4883-ac7d-3f606d8e3303", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.05 }, "kind": "title", "text": "A Leading Provider of Cell-Engineering Platform Technologies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ed9d2df-ab7f-460d-98ed-004f300fa4dd", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1a3019d7-2fb3-472b-b796-28256dcf85b1", "evidence": "The slide provides a brief overview of the company's technology and business model.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:12.528579+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "setup", "title": "The slide uses a dual-track timeline showing the progression of Cell Therapy and Drug Discovery business segments alongside corporate milestones.", "function": "establish_context", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "balanced", "densityScore": 35, "componentCount": 4, "textChars": 228, "nDataPoints": 3, "notes": "The slide uses a dual-track timeline showing the progression of Cell Therapy and Drug Discovery business segments alongside corporate milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:54.906+00", "seconds": 2.253, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/4", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-4", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.85, "x": 0.1, "y": 0.2 }, "kind": "chart", "text": "Corporate history timeline from 1999 to 2022", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:54.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33572560-cd5b-4db1-aba8-97db0abecdd0", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.18, "x": 0.8, "y": 0.04 }, "kind": "image", "text": "MaxCyte and Nasdaq logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:54.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e6fd4bff-045d-4720-ad7f-57b7ffa95075", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.14, "y": 0.2 }, "kind": "list", "text": "23 SPL Partnerships Signed Since 2017; 125 Employees*; 30+ Field Sales and Application Scientists*", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:54.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a6fe1f1a-9133-45ca-9f14-9677fdda0146", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.77, "x": 0.04, "y": 0.05 }, "kind": "title", "text": "Who We Are - Collaborative, Innovative and Experienced Partner", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:54.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "20827b30-d98d-4e38-8cfa-3d78a3fb7c88", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "0f75232c-4e64-4c44-bc50-ae26fbecf01f", "evidence": "Chronological progression of company milestones", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:54.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "evidence", "title": "The slide uses a process flow diagram to show the funnel from potential partnerships to active clinical programs.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 5, "textChars": 390, "nDataPoints": 4, "notes": "The slide uses a process flow diagram to show the funnel from potential partnerships to active clinical programs.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:55.256+00", "seconds": 2.458, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/5", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-5", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "diagram", "text": "75+ Potential SPL Partnerships; 23 SPL Partnerships signed since 2017; 125+ Programs; 16 Programs currently active in the clinic", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ac2d455-7e3f-4b87-bc65-374ba2f5385f", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.9, "x": 0.05, "y": 0.65 }, "kind": "image", "text": "Partner logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b8600dea-7618-4e60-a288-7bf2cbe3b2c5", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.13, "y": 0.55 }, "kind": "metric", "text": "23 Strategic Platform Licenses (SPL) Partnerships, including 5 so far in 2023", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a516815f-1664-40cd-95ca-4356d87f5dc1", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.48 }, "kind": "source-note", "text": "**Number of gene-modified ex-vivo cell therapy companies using non-viral delivery. *Updated as of December 31, 2022", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1f84f5bf-40cf-4293-8197-0261f2882801", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.69, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "MaxCyte: Leading Partner for Complex Cellular Engineering", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2f3b9a50-926e-44dd-a738-55382f358bfc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Traction", "beatId": "dfb91984-6b87-4a1e-a5ea-23a6ffe055b6", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": null, "evidence": "Slides 5-6 showcase MaxCyte's traction and value creation.", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 6, "type": "evidence", "title": "The chart shows a cumulative growth of partnerships over time from 2017 to 2023.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 5, "textChars": 917, "nDataPoints": 1, "notes": "The chart shows a cumulative growth of partnerships over time from 2017 to 2023.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:55.519+00", "seconds": 2.66, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/6", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-6", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.68, "w": 0.44, "x": 0.51, "y": 0.14 }, "kind": "chart", "text": "Cumulative Potential Pre-CML Milestones", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Area chart", "slug": "area", "status": "active", "canonId": "019de52c-ff89-71e0-911e-5cab78b90f53", "version": 1, "description": null }, "framework": null }, "subkind": "area", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.519+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8e24e43-79ec-41bb-9113-3e6c88b118d0", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.4, "x": 0.08, "y": 0.32 }, "kind": "list", "text": "Potential value of pre-commercial (clinical development) milestones from SPLs: ~$2B\nSales-based payments upon partner's product commercialization\nRecurring revenues from lease of instruments and sales of single-use disposables that grow with program success\nMilestone revenue is MaxCyte's highest growth revenue stream", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.519+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "585e31cb-f7cf-49f6-ae31-dd549ecb520e", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.35, "x": 0.14, "y": 0.18 }, "kind": "paragraph", "text": "Licensing deals include significant development milestones and high-value participation in future commercial success of partners", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.519+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c7bcc42e-36e3-4513-a9dc-815c335e6912", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.08, "y": 0.83 }, "kind": "source-note", "text": "**Casebia/CRISPR's SPL partnership (signed in 2017) included the rights to use MaxCyte's technology in the development of exa-cel (formerly known as CTX001). As announced in the press release on September 28th, 2022, Vertex has signed an SPL agreement with MaxCyte – Vertex has obtained the clinical and commercial rights to use MaxCyte's technology for the development of exa-cel (formerly known as CTX001).", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.519+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "75474508-13e0-480b-a995-a3a1f8b4e63f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "Value Creation from SPLs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.519+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0e703a2-550c-4bfa-b69d-bb24cfa0b632", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Traction", "beatId": "dfb91984-6b87-4a1e-a5ea-23a6ffe055b6", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": null, "evidence": "Slides 5-6 showcase MaxCyte's traction and value creation.", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 7, "type": "resolution", "title": "Includes a mix of historical data, pipeline metrics, and future projections.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 89, "componentCount": 12, "textChars": 612, "nDataPoints": 10, "notes": "Includes a mix of historical data, pipeline metrics, and future projections.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:56.434+00", "seconds": 3.547, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/7", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-7", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.5, "x": 0.05, "y": 0.48 }, "kind": "chart", "text": "Projected sales of gene-modified cell therapies by 2026", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5992c0a-dcf5-4302-8f53-53dbb2aa595f", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.38, "x": 0.6, "y": 0.48 }, "kind": "list", "text": "2022 was focused on innovation and complexity: \"Other\" cell types grew 129% in 2022; Allogeneic therapies increased 33% vs autologous 23%; Rapid growth in cell targets.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0239d684-0e7c-4eec-bc8a-cadc599a2d9e", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.3, "y": 0.18 }, "kind": "metric", "text": "650+", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "687e9c03-940e-41ae-b118-88003c366a36", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.08, "x": 0.52, "y": 0.18 }, "kind": "metric", "text": "6", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "76d88435-1bd4-4fda-8c90-87410bcdc48e", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.08, "y": 0.18 }, "kind": "metric", "text": "1,800+", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9935647a-8684-4aeb-b838-9b91119a0847", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.74, "y": 0.28 }, "kind": "metric", "text": "$12.6B", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b25e0b62-2dfa-4f7d-8e42-760cc66a7948", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "Source: Evaluate Pharma; Alliance for Regenerative Medicine; Saez-Ibañez, Nature News, June 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "42a28279-5ee8-4e2c-9e66-9695fcd566d6", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.22, "x": 0.26, "y": 0.28 }, "kind": "subtitle", "text": "Genetically-modified cell therapies in preclinical development", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "344e367e-48d0-4255-918d-ba2ad844831b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.28, "x": 0.67, "y": 0.2 }, "kind": "subtitle", "text": "Total amount of 2022 global financings for cell and gene therapy companies", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8306fc4a-834a-431c-8d7d-990beda6e1f9", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.18, "x": 0.06, "y": 0.28 }, "kind": "subtitle", "text": "Genetically-modified cell therapies in development", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "963e16c2-9dc8-443d-9513-4968917b48b8", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.15, "x": 0.49, "y": 0.28 }, "kind": "subtitle", "text": "New cell and gene therapies approved in 2022", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bc4686e7-b1b9-443a-9a2a-f94416f29266", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "Continued Investment in Cell and Gene Therapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1f6962b8-aac9-4812-a94f-49df946971cb", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 8, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Problem", "beatId": "993aae5c-8a2b-466e-8ac3-325090cd909e", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 7-8 discuss market sizing and industry challenges.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Market Size", "beatId": "20322ef1-1a83-4f62-84a0-1210f95cd1b6", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Slide 7 discusses market sizing.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "01f711fa-869f-4bfb-90f0-c7ddf9b8181f", "evidence": "The deck implies that not investing in cell-based therapies would mean missing out on significant market opportunity.", "position": 0, "objective": "What if we don't invest in cell-based therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:41.4904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "resolution", "title": "Uses a before-after-bridge style framing to contrast pain points with platform capabilities.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 25, "componentCount": 4, "textChars": 167, "nDataPoints": 0, "notes": "Uses a before-after-bridge style framing to contrast pain points with platform capabilities.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:55.74+00", "seconds": 2.413, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/8", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-8", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.88, "x": 0.06, "y": 0.25 }, "kind": "list", "text": "Four rows mapping industry challenges to MaxCyte solutions using icons and descriptive text.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Comparison list", "slug": "comparison", "status": "active", "canonId": "019de52c-fce7-733e-99d3-030a104727bf", "version": 1, "description": null }, "framework": null }, "subkind": "comparison", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.74+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7048578a-2b6e-4629-876f-849dbd6ad678", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.15, "x": 0.06, "y": 0.18 }, "kind": "title", "text": "Challenges", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.74+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0442aa04-8997-47da-9d3f-16a63e2ea554", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.25, "x": 0.47, "y": 0.18 }, "kind": "title", "text": "MaxCyte's Solutions", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.74+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e8dd5cf-e6b6-40d8-9dc9-6743a0304589", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "ExPERT™ Platform Addresses Industry Challenges", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:55.74+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee52a7a7-cbf2-4c4c-a66d-b1bd167b5ff9", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "55164560-7bea-4e95-82d4-d18318ef3530", "evidence": "Maps specific industry pain points to corresponding product solutions.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:55.74+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "before-after-bridge" } ], "arcBeats": [ { "to": 8, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Problem", "beatId": "993aae5c-8a2b-466e-8ac3-325090cd909e", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 7-8 discuss market sizing and industry challenges.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Solution", "beatId": "c85bce06-a0b6-4a3f-abe1-f93499e324ad", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 8-9 present the ExPERT platform as a solution to industry challenges.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "01f711fa-869f-4bfb-90f0-c7ddf9b8181f", "evidence": "The deck implies that not investing in cell-based therapies would mean missing out on significant market opportunity.", "position": 0, "objective": "What if we don't invest in cell-based therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:41.4904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "resolution", "title": "The slide highlights the transition from RUO to cGMP capabilities across the product line.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 4, "textChars": 803, "nDataPoints": 6, "notes": "The slide highlights the transition from RUO to cGMP capabilities across the product line.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:56.522+00", "seconds": 3.044, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/9", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-9", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.55, "x": 0.4, "y": 0.15 }, "kind": "image", "text": "ExPERT Instrument Portfolio (ATx, STx, GTx, VLx)", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.522+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fae2145f-e7d8-40a0-a3c2-c022ca267d6c", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.55, "x": 0.4, "y": 0.55 }, "kind": "list", "text": "High Performance: >90% transfection efficiencies, >90% cell viabilities, Computer-controlled system. Flexibility: Single, fully-defined, animal component-free buffer, Pre-loaded library. Scalability: 75,000 to 7 million cells in seconds, Up to 20 billion cells in <30 mins, Up to 200 billion cells in <30 mins. High Quality: Sterile, single-use PAs, Closed, cGMP-compliant, ISO-certified, CE marked, FDA Master File.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.522+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d3e16af1-b094-4cfb-befb-b789bbfecb8b", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.35, "x": 0.04, "y": 0.18 }, "kind": "list", "text": "Launched in 2019 based on MaxCyte’s proprietary Flow Electroporation® technology... Leverages the reversible permeability... Universally delivers molecules... Agnostic to cell type... Enables customers to use a single platform... Supported by a robust intellectual property portfolio", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.522+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eea50005-045f-43db-9e3b-9874d09d357e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "The ExPERT™ Platform Enabling Non-Viral Cell Engineering", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.522+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6926f7a2-7ab2-4fd9-8d71-e3b994b7f96f", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "778bc7f7-82ab-4f9e-b13f-7f4493657027", "evidence": "The ExPERT™ Platform Enabling Non-Viral Cell Engineering, targeted at customers in the cell therapy and drug discovery markets.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:30.286058+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Value Proposition Canvas", "slug": "value-proposition-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-85a9-713f-8a1c-b6e5af5cc6cd", "version": 1, "bodyDocId": null, "description": "Mapping customer jobs/pains/gains to your value proposition", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "dbb3d6b9-666f-4844-8a79-f0ec2fc91d06", "evidence": "Enabling customers to use... Agnostic to cell type... High Performance: >90% transfection efficiencies, >90% cell viabilities", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:34:30.33202+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Solution", "beatId": "c85bce06-a0b6-4a3f-abe1-f93499e324ad", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 8-9 present the ExPERT platform as a solution to industry challenges.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "01f711fa-869f-4bfb-90f0-c7ddf9b8181f", "evidence": "The deck implies that not investing in cell-based therapies would mean missing out on significant market opportunity.", "position": 0, "objective": "What if we don't invest in cell-based therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:41.4904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "setup", "title": "The slide explicitly labels the model as 'Razor/Razor Blade Economics'.", "function": "present_solution", "rawType": "business_model", "block": null, "metadata": { "slideType": "business_model", "slideTypeCanon": { "name": "Business model", "slug": "business_model", "status": "active", "canonId": "019de52d-0fa6-7104-86d0-e5781f8b8b45", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 6, "textChars": 446, "nDataPoints": 0, "notes": "The slide explicitly labels the model as 'Razor/Razor Blade Economics'.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:56.317+00", "seconds": 2.672, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/10", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-10", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.9, "x": 0.036, "y": 0.52 }, "kind": "framework", "text": "Drug Discovery Revenue Model: Instrument sale (ATx/STx) + Single-use disposables (processing assemblies) = Razor/Razor Blade Economics", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63134664-97a5-4296-a15d-fb087645cb52", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.4, "x": 0.44, "y": 0.2 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3c57dca8-58a8-4d4e-9c0d-4b36855a6a91", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.23, "y": 0.64 }, "kind": "image", "text": "ATx Small/mid-scale RUO", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d093affb-86a9-4710-98ba-0aff73621240", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.48, "y": 0.64 }, "kind": "image", "text": "STx Full scale RUO", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e675fe9c-0d61-413a-a3da-fb1f70b21638", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.37, "x": 0.036, "y": 0.21 }, "kind": "paragraph", "text": "DRUG DISCOVERY & DEVELOPMENT - Cells used to Discover / Produce Drug Products\nKey Applications: Cell-based assays, protein and antibody production, vaccine development\nCustomer base: Large/small biopharma and academic centers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b495829-131c-4a3e-aee7-5259187efd83", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.615, "x": 0.036, "y": 0.09 }, "kind": "title", "text": "MaxCyte Business Model – Drug Discovery Market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "135b0148-171a-4c46-a161-cd39fe25394f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b42f0d81-ac18-4c0f-aff2-d8d21b96c41d", "evidence": "Explicitly stated as 'Razor/Razor Blade Economics' in the revenue model flow.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:56.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "razor-razor-blade" } ], "arcBeats": [ { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Business Model", "beatId": "976459c1-7ff0-4493-b615-fc2c763afd88", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "Slides 10-11 present MaxCyte's business model.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 11, "type": "setup", "title": "Uses the 'Razor/Razor Blade' business model framework.", "function": "present_solution", "rawType": "business_model", "block": null, "metadata": { "slideType": "business_model", "slideTypeCanon": { "name": "Business model", "slug": "business_model", "status": "active", "canonId": "019de52d-0fa6-7104-86d0-e5781f8b8b45", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 5, "textChars": 562, "nDataPoints": 0, "notes": "Uses the 'Razor/Razor Blade' business model framework.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:27:05.347+00", "seconds": 11.534, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/11", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-11", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.92, "x": 0.045, "y": 0.35 }, "kind": "framework", "text": "Preclinical and Academic Revenue Model: Instrument Sale (ATx/GTx) + Single-use Disposables = Razor/Razor Blade Economics", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:05.347+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "394657ef-bf0e-4207-8ebf-0cecef3a5394", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.92, "x": 0.045, "y": 0.65 }, "kind": "framework", "text": "SPL Partnership Model: Annual Instrument License Fee (GTx) + Single-use Disposables + Strategic Partnership Terms = Razor/Razor Blade Economics and Share of Therapeutic Economics", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:05.347+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "baa604cf-c8de-4bce-9199-02125024ff9e", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.3, "x": 0.22, "y": 0.42 }, "kind": "image", "text": "Product images of ATx and GTx instruments", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:05.347+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0972150b-4e5a-49d3-8f68-e8431efa6bfa", "parentComponentId": null }, { "bbox": { "h": 0.11, "w": 0.58, "x": 0.045, "y": 0.17 }, "kind": "paragraph", "text": "CELL THERAPY – Cell itself is the Drug\nKey Applications: Ex-Vivo Engineered Cell Therapies\nCustomer Base: Leading global cell therapy developers and academic translational centers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:05.347+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a90fa49-ae1f-418e-b753-3a2365fd1596", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.59, "x": 0.045, "y": 0.07 }, "kind": "title", "text": "MaxCyte Business Model – Cell Therapy Market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:05.347+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "37bd929b-3045-44b5-984f-2d67bb22ae29", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "73a0c7f9-60ae-428d-9400-24a4ef15afee", "evidence": "Explicit mention of 'Razor/Razor Blade Economics' and structure of recurring revenue from disposables.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:27:05.347+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "razor-blade-model" } ], "arcBeats": [ { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Business Model", "beatId": "976459c1-7ff0-4493-b615-fc2c763afd88", "matchId": "054d6cfa-994c-4c82-b326-94680eda4ef4", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "Slides 10-11 present MaxCyte's business model.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 12, "type": "analysis", "title": "The chart uses a timeline-based progression from early clinical to commercial phase.", "function": "analyze_data", "rawType": "revenue_buildup", "block": null, "metadata": { "slideType": "revenue_buildup", "slideTypeCanon": { "name": "Revenue buildup", "slug": "revenue_buildup", "status": "active", "canonId": "019de52d-0acd-70b8-a81d-62d89840409b", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 5, "textChars": 320, "nDataPoints": 0, "notes": "The chart uses a timeline-based progression from early clinical to commercial phase.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:57.007+00", "seconds": 3.125, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/12", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-12", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.58, "x": 0.16, "y": 0.2 }, "kind": "chart", "text": "Stacked area chart showing revenue growth over time", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked area chart", "slug": "area-stacked", "status": "active", "canonId": "019de52c-ffb1-75fa-a614-76782f418cf1", "version": 1, "description": null }, "framework": null }, "subkind": "area-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.007+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9279884c-ab79-4786-a67a-996f3fa10bf0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.8, "y": 0.04 }, "kind": "image", "text": "MaxCyte", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.007+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "03e7cc4b-a524-4ada-864b-22d40ee766cb", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.2, "x": 0.75, "y": 0.33 }, "kind": "legend", "text": "Cell Therapy Partner Program Value Schematic: Instruments, Milestones, Sales-Based Payments", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.007+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72ced5f9-4f3b-4f73-a27a-293d294723a6", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.6, "x": 0.1, "y": 0.2 }, "kind": "list", "text": "Early Clinical (Years 1-3), Mid-late Clinical (Years 3-5+), Approval (Year 5+), Commercial Phase", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.007+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "34632aa2-7c19-43c1-8200-247ee1cca7f0", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.55, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "Example: Typical Single-Product Revenues from a Representative License Deal", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.007+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d92a8cb-3536-4666-9ea5-9247c06749fd", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "67b4280f-eb14-4416-ab17-f14bbc581877", "evidence": "Stacked area chart showing revenue growth over time", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:34:30.506148+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "188b8601-38ed-4782-a11b-21cf4fa502ec", "evidence": "The chart maps revenue stages against a chronological progression of clinical development.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:57.007+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 13, "type": "analysis", "title": "The chart uses a stacked bar format to distinguish between pre-commercial and commercial revenue components.", "function": "analyze_data", "rawType": "revenue_buildup", "block": null, "metadata": { "slideType": "revenue_buildup", "slideTypeCanon": { "name": "Revenue buildup", "slug": "revenue_buildup", "status": "active", "canonId": "019de52d-0acd-70b8-a81d-62d89840409b", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 71, "componentCount": 6, "textChars": 612, "nDataPoints": 6, "notes": "The chart uses a stacked bar format to distinguish between pre-commercial and commercial revenue components.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:57.025+00", "seconds": 3.059, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/13", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-13", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.42, "x": 0.29, "y": 0.32 }, "kind": "chart", "text": "Example Partnerships NPV", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6dceee38-8b07-4933-94a9-5f4f5cc18f70", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.05, "y": 0.34 }, "kind": "list", "text": "Higher Value Partnership Influencing Factors: Large indications, Instrument & consumables utilization", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "029220d2-96d1-4fa7-8809-9bf1e6c6432b", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.72, "y": 0.34 }, "kind": "list", "text": "Lower Value Partnership Influencing Factors: Small indications, Conservative commercial milestones, Lower utilization", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9773194f-8738-4bca-8963-89339b277f2b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.04, "y": 0.77 }, "kind": "source-note", "text": "*10-year NPV **Weighted based on the expected split of commercial programs in Year 6 (assuming earliest approval); Assumes first 5-years of standard ten-year biotech sales curve", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "654a30b4-c545-4e86-a81c-b91bfaa2452a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.35, "y": 0.18 }, "kind": "subtitle", "text": "Assumes 6 programs per SPL launching 1 year apart, 2 fail in preclinical, 4 enter clinical, and 1 reaches commercial", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "862c9fdd-1fa3-4fac-8323-71c377c8169b", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.65, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "SPL Partnerships Offer Significant Revenue Upside, Particularly in Commercial", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ce64f33-2135-42e8-9a81-ff027c0c064d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 14, "type": "evidence", "title": "The slide uses donut charts to visualize the distribution of milestone events across IND, Pre-Pivotal, and Pivotal or Later phases.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 71, "componentCount": 7, "textChars": 455, "nDataPoints": 6, "notes": "The slide uses donut charts to visualize the distribution of milestone events across IND, Pre-Pivotal, and Pivotal or Later phases.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:57.482+00", "seconds": 3.441, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/14", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-14", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.07, "w": 0.28, "x": 0.41, "y": 0.815 }, "kind": "callout", "text": "50 potential SPL pre-commercial milestone events over the next 3 years", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.482+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "24b7c9c4-626d-438c-b53e-b8ff05f5d2f5", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.28, "x": 0.11, "y": 0.315 }, "kind": "chart", "text": "2017-2022 milestone distribution", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Donut chart", "slug": "donut", "status": "active", "canonId": "019de52d-0006-752c-9528-0fef476b8004", "version": 1, "description": null }, "framework": null }, "subkind": "donut", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.482+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c27c54b-0d47-4a40-b6cb-500d33b9712f", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.28, "x": 0.41, "y": 0.315 }, "kind": "chart", "text": "2023-2025 milestone distribution", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Donut chart", "slug": "donut", "status": "active", "canonId": "019de52d-0006-752c-9528-0fef476b8004", "version": 1, "description": null }, "framework": null }, "subkind": "donut", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.482+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a07b7c8e-ee23-4c3e-afa9-8abf37da6808", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.23, "x": 0.73, "y": 0.315 }, "kind": "list", "text": "Representative SPL Payments: IND: Low to Mid 6-figure milestones; Pre-Pivotal: Low 7-figure milestones; Pivotal or Later: Low to Mid 7-figure milestones", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.482+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f7b5765-e617-469d-a529-2cf361139ace", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.42, "x": 0.04, "y": 0.905 }, "kind": "source-note", "text": "As of March 2023 / Pre-Pivotal includes Phase 1, Phase 2 and first manufacturing events", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.482+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d41f8d5-861f-4683-bb91-d12b53867b3f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.26, "x": 0.04, "y": 0.12 }, "kind": "subtitle", "text": "Total Milestone Events by Phase", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.482+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8f9147c-d301-46ab-af30-e687c55f648d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.68, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "MaxCyte Partnership Pre-Commercial Milestone Events", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.482+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "89e2f6ec-5d28-4a21-a9af-67f6fb6f4647", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 15, "type": "resolution", "title": "The slide uses a wave-based visual metaphor to represent sequential growth phases.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 82, "componentCount": 7, "textChars": 1115, "nDataPoints": 5, "notes": "The slide uses a wave-based visual metaphor to represent sequential growth phases.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:58.039+00", "seconds": 3.98, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/15", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-15", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.19, "x": 0.4, "y": 0.18 }, "kind": "list", "text": "Third Wave: 8 Potential Approved Partner Programs, Launch Potential: 2028-2030, SPL Programs: Undisclosed, Example Indications: Solid Tumors, Lymphoma/Leukemia, Multiple Myeloma, Sickle Cell Disease, Beta-Thalassemia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.039+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f0b902d-189e-49a0-840e-1da2cd5d8523", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.19, "x": 0.21, "y": 0.18 }, "kind": "list", "text": "Second Wave: 7 Potential Approved Partner Programs, Launch Potential: 2025-2027, SPL Programs: SPL Partner A Program 1, SPL Partner A Program 2, Caribou's CB-010, Editas' EDIT-301, Precision Bio's Azer-cel, Vor's Trem-cel, Invios' APN401, Indications: Lymphoma/Leukemia, Solid Tumors, Sickle Cell Disease, Beta-Thalassemia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.039+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "141ec9d2-a4f1-412c-a56d-78702495e6e3", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.19, "x": 0.02, "y": 0.18 }, "kind": "list", "text": "First Wave: 1 Potential Approved Partner Program, Launch Potential: 2024, SPL Program: Vertex's Exa-Cel, Indications: Sickle Cell Disease, Beta-Thalassemia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.039+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "178a1fc3-b1b0-4443-a76e-6fff2f1b9c2c", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.19, "x": 0.59, "y": 0.18 }, "kind": "list", "text": "Fourth Wave: 20+ Additional Preclinical Partner Programs, Launch Potential: 2030+, Example Indications: Solid Tumors, Autoimmune Diseases, Neurodegenerative Diseases, Genetic Diseases, Lymphoma/Leukemia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.039+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7c282ec0-b348-497a-be1d-0b9b8dbc2c65", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.19, "x": 0.78, "y": 0.18 }, "kind": "list", "text": "Fifth Wave: Additional Licensed Programs and New Partnerships Signed, Launch Potential: 2032+", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.039+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c62e7f83-0d35-459e-8146-46ab111e859c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.02, "y": 0.92 }, "kind": "source-note", "text": "Source: Evaluate Pharma", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.039+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "783c6ee6-67e9-4d82-966b-9f68c62442ed", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.68, "x": 0.02, "y": 0.04 }, "kind": "title", "text": "MaxCyte Partnerships – Near and Long-Term Revenue Potential with Strong Upside in Commercial Opportunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.039+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "32fb70ea-10bd-4d87-850c-69f6f9860f88", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "29772201-3ded-4195-b4a3-a9c7d3c34661", "evidence": "Sequential waves representing future growth phases", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:58.039+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 16, "type": "evidence", "title": "The diagram uses concentric circles to represent clinical phases and color-coded dots to represent cell approaches (allogeneic vs autologous).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 4, "textChars": 313, "nDataPoints": 14, "notes": "The diagram uses concentric circles to represent clinical phases and color-coded dots to represent cell approaches (allogeneic vs autologous).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:56.961+00", "seconds": 2.853, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/16", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-16", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.65, "x": 0.25, "y": 0.15 }, "kind": "diagram", "text": "Concentric circle diagram showing clinical trials", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9478196-21e2-4500-b2d4-93275c325cec", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.06, "y": 0.18 }, "kind": "list", "text": "Clinical Phase: Phase 1, Phase 1/2, Pivotal. Cell Approach: Allogeneic, Autologous.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5263ca5a-716b-493a-bfac-4de0f2b47abe", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.03, "y": 0.7 }, "kind": "paragraph", "text": "As of March 2023 / Includes Commercial and Academic Clinical Trials. Program received IND clearance but is not yet listed on clinicaltrials.gov", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "85f0d135-bf56-489b-8a64-93a33f9c4f20", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.48, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "MaxCyte-Enabled Active Clinical Trials", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:56.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd61d21d-1838-4074-8ca8-c9fab8d51347", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 17, "type": "evidence", "title": "The slide uses a Vitruvian Man-style graphic to represent the breadth of therapeutic applications.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 8, "textChars": 658, "nDataPoints": 2, "notes": "The slide uses a Vitruvian Man-style graphic to represent the breadth of therapeutic applications.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:27:01.585+00", "seconds": 7.167, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/17", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-17", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.42, "w": 0.22, "x": 0.23, "y": 0.28 }, "kind": "image", "text": "Vitruvian Man graphic", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:01.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2d236e78-27fe-48c1-aaa6-85f6206ef41a", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.15, "x": 0.45, "y": 0.27 }, "kind": "list", "text": "Infectious Disease: HIV. Solid Tumors: Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Other Solid Tumors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:01.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4ea1a817-ac3c-4b05-8369-221e38ddabac", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.67, "y": 0.28 }, "kind": "list", "text": "ARCUS, Base-editing (CRISPR), CRISPR, RNA-Based Engineering, TALENS, Zinc Finger Nucleases (ZFNs)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:01.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7b2920af-2b02-4687-97aa-fa66188fb2c9", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.25, "x": 0.04, "y": 0.27 }, "kind": "list", "text": "Genetic Diseases: Beta-Thalassemia, Sickle Cell Disease, Chronic Granulomatous Disease (CGD). Hematological Malignancies: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, T-Cell Lymphoma", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:01.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d8b1d645-28df-4a48-a3aa-66d6df247da5", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.22, "x": 0.69, "y": 0.69 }, "kind": "metric", "text": "2023/2024", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:01.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "112b552a-b382-48ab-982a-84c373773c5b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.14, "x": 0.27, "y": 0.66 }, "kind": "metric", "text": "1,000+", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:01.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1a48bbd0-0f74-43d2-8b25-9147a6f3fa10", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.65, "y": 0.57 }, "kind": "paragraph", "text": "First MaxCyte-Enabled Therapy is expected to be approved as early as", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:01.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0ea97d39-41c3-423f-bcd1-c245aa95b923", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.65, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "MaxCyte Enables Next-Generation Cell Therapies Across a Variety of Diseases", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:27:01.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d81c3a19-0ff2-4ebb-8d05-93994e42fdaa", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "bcb47f47-ac2f-41fb-b413-80a39daa7a62", "evidence": "The slide contains lists of bullet points highlighting various diseases and technologies.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:39:21.409417+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 18, "type": "setup", "title": "The slide uses a process diagram to anchor the business updates.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 6, "textChars": 361, "nDataPoints": 5, "notes": "The slide uses a process diagram to anchor the business updates.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:58.341+00", "seconds": 3.576, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/18", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-18", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.8, "x": 0.1, "y": 0.2 }, "kind": "diagram", "text": "Prepare/Isolate, Concentrate, Culture, Cryopreserve, Thaw/Dose", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.341+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac65e04c-c41a-4ec8-a490-9f3b63006bc3", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.45, "x": 0.5, "y": 0.48 }, "kind": "list", "text": "Revenue guidance $34-36M; Launch new PAs; VLx launch; Global commercial support; Core technology expansion.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.341+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "37ce4168-211c-4973-88bc-f0f305f90e5c", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.45, "x": 0.04, "y": 0.48 }, "kind": "list", "text": "Five SPL partnerships announced year-to-date; Total cash $216M; CFO appointment; ESG report published.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.341+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eddbd3da-d29b-422c-8361-d79aa177a559", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.6, "y": 0.42 }, "kind": "title", "text": "2023 Guidance and 2023+ Outlook", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.341+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1eac7c16-3ad8-4753-b4b6-cd822adfa313", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.04, "y": 0.05 }, "kind": "title", "text": "2023 YTD Summary and Outlook for 2023+", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.341+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b16009b-0c97-41c5-a3b4-492e7b3844d9", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.16, "y": 0.42 }, "kind": "title", "text": "2023 YTD Achievements", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:58.341+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9b248e0a-a2f8-4ff2-82fc-eb520620c478", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "815b7d7a-ba73-4c1a-ad13-f2017e833ce2", "evidence": "2023 YTD Summary and Outlook for 2023+, list/bullet: Revenue guidance $34-36M; Launch new PAs; VLx launch; Global commercial support; Core technology expansion.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:30.723208+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "3401ed1b-7432-4fe4-9e40-6dd3eaac01b6", "evidence": "The slide uses a 6-step linear process flow to represent the business workflow.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:26:58.341+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "process" } ], "arcBeats": [], "loops": [ { "to": 19, "from": 18, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null }, "matchId": "e0b404df-b36e-43ac-bec8-608ea5c66a7d", "evidence": "Slides 18-19 discuss 2023 YTD summary and outlook, implying that now is a good time to invest.", "position": 1, "objective": "Why now is the time to invest in MaxCyte", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:41.532647+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "setup", "function": "state_next_steps", "rawType": "closing_ask", "block": null, "metadata": { "slideType": "closing_ask", "slideTypeCanon": { "name": "Closing ask", "slug": "closing_ask", "status": "active", "canonId": "019de52d-0aa4-750f-8aa1-8d622dd99f5c", "version": 1, "description": null }, "function": "state_next_steps", "functionCanon": { "name": "State next steps", "slug": "state_next_steps", "status": "active", "canonId": "019de52d-14ca-70ac-b534-971f458cdf29", "version": 1, "description": null }, "density": "balanced", "densityScore": 39, "componentCount": 4, "textChars": 415, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:57.573+00", "seconds": 2.712, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/19", "deck": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f", "deckAnchor": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-19", "deckJson": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.7, "x": 0.15, "y": 0.65 }, "kind": "disclaimer", "text": "© 2023 MaxCyte, Inc. All rights reserved. MaxCyte®, MaxCyte ATx®, MaxCyte GT®, MaxCyte STx®, MaxCyte VLX®, Flow Transfection®, Flow Electroporation®, exPERT®, ATx®, STx® and GTx®, are registered trademarks of MaxCyte, Inc. MaxCyte GTx™, MaxCyte STx™, ExPERT ATx™, ExPERT GTx™, ExPERT STx™, ExPERT VLx™, ExPERT™, ATx™, GTx™, STx™, VLx™, and VLx™ are trademarks of MaxCyte, Inc.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b60e7f6d-6490-412e-9d4e-c64932e663e7", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.08, "y": 0.875 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a7dd06de-1c86-47c4-88c7-bf06105499f8", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.16, "x": 0.42, "y": 0.55 }, "kind": "paragraph", "text": "ir@maxcyte.com", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "46cebae1-5420-4720-a546-033ee6f50cb8", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.32, "x": 0.34, "y": 0.26 }, "kind": "title", "text": "Thank you! Any questions?", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:57.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "585cffba-4e4b-4db9-a280-4ab0d755ebc5", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Storytelling: the closing ask", "slug": "closing-ask", "status": "active", "bestFor": null, "canonId": "019df269-24e0-70ab-8dd9-983832c1c665", "version": 1, "bodyDocId": "019df269-24bc-7554-b88d-245127606b8d", "description": "The single most important slide in the deck — after the cover. The final", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "c54bc30f-cba8-4154-a23a-0a3440e66f3a", "evidence": "Thank you! Any questions?, title/headline: Thank you! Any questions?", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:30.810179+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 19, "from": 18, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null }, "matchId": "e0b404df-b36e-43ac-bec8-608ea5c66a7d", "evidence": "Slides 18-19 discuss 2023 YTD summary and outlook, implying that now is a good time to invest.", "position": 1, "objective": "Why now is the time to invest in MaxCyte", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:41.532647+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true } ], "arcBeats": [ { "from": 7, "to": 8, "label": "Problem", "description": "Slides 7-8 discuss market sizing and industry challenges." }, { "from": 8, "to": 9, "label": "Solution", "description": "Slides 8-9 present the ExPERT platform as a solution to industry challenges." }, { "from": 7, "to": 7, "label": "Market Size", "description": "Slide 7 discusses market sizing." }, { "from": 10, "to": 11, "label": "Business Model", "description": "Slides 10-11 present MaxCyte's business model." }, { "from": 5, "to": 6, "label": "Traction", "description": "Slides 5-6 showcase MaxCyte's traction and value creation." } ], "loops": [ { "from": 7, "to": 9, "label": "Cost Of Inaction", "description": "What if we don't invest in cell-based therapies?" }, { "from": 18, "to": 19, "label": "Why Now", "description": "Why now is the time to invest in MaxCyte" } ] }